Is the use of specialized nutritional formulations a cost-effective strategy? A national database evaluation
- PMID: 15709550
- DOI: 10.1177/01486071050290S1S81
Is the use of specialized nutritional formulations a cost-effective strategy? A national database evaluation
Abstract
Background: We apply currently published clinical outcomes data to length of stay and hospital cost to determine the potential economic benefit associated with the use of specialized nutritional formulations in elective surgical, trauma, and medical patients. Although the use of immune-modulating formulations has repeatedly shown favorable clinical outcomes, including decreased complications (both infectious and noninfectious), length of stay (both ICU and total days), and ventilator days, the cost-effectiveness of nutritional modulation of the immune response in a US-based population has not previously been explored.
Methods: Data for the current study were obtained from a large national database with 126 member hospitals and data from over 1 million patients. Data extracted from the database included patient type (surgical, medical, and trauma) and subservice, whether the hospital stay was "complicated" or "uncomplicated" (as determined by diagnosis-related groups and International Classification of Diseases, Ninth Revision coding), mean length of stay, mean cost, and incremental cost per complication experienced. The clinical outcomes measures from 3 major peer-reviewed studies were then applied to the cost data in order to determine the cost savings associated with the use of specialized nutritional formulations in each of the patient populations. Additionally, cost data were segmented by region of the United States (New England, mid-Atlantic, South, Midwest, Southwest, and West) and by primary focus of the health care facility (academic, indigent care, large community) to enable more meaningful cost comparisons.
Results: For the medical patient population, according to the published rate of 51% decrease in risk of infectious complications and a decreased length of hospital stay of 9.7 days, net cost savings (after accounting for the increased costs of administering immune modulating formula) is $2066. The same calculations were done for surgical and trauma patients, with $688 and $308 net cost savings per patient, respectively. These figures assume a base infection rate of 5%. Expected cost savings vary markedly for deviations in base infection rate and slightly for differences in facility type or region of the country.
Conclusions: This study demonstrates that specialized nutritional formulations are a cost-effective way for hospitals to improve clinical outcomes while reducing resource consumption and total cost. These benefits are observable in all patient types, all facility types, and all regions of the United States.
Similar articles
-
Cost-effectiveness analysis of immune-modulating nutritional support for gastrointestinal cancer patients.Clin Nutr. 2014 Aug;33(4):649-54. doi: 10.1016/j.clnu.2013.09.001. Epub 2013 Sep 13. Clin Nutr. 2014. PMID: 24074548
-
Economic evaluation of individualized nutritional support in medical inpatients: Secondary analysis of the EFFORT trial.Clin Nutr. 2020 Nov;39(11):3361-3368. doi: 10.1016/j.clnu.2020.02.023. Epub 2020 Feb 25. Clin Nutr. 2020. PMID: 32147200 Clinical Trial.
-
Estimating the economic impact of a half-day reduction in length of hospital stay among patients with community-acquired pneumonia in the US.Curr Med Res Opin. 2009 Sep;25(9):2151-7. doi: 10.1185/03007990903102743. Curr Med Res Opin. 2009. PMID: 19601711
-
Economic study in surgical patients of a new model of nutrition therapy integrating hospital and home vs the conventional hospital model.JPEN J Parenter Enteral Nutr. 2005 Jan-Feb;29(1 Suppl):S96-105. doi: 10.1177/01486071050290S1S96. JPEN J Parenter Enteral Nutr. 2005. PMID: 15709552 Review.
-
Cost savings associated with nutritional support in medical inpatients: an economic model based on data from a systematic review of randomised trials.BMJ Open. 2021 Jul 9;11(7):e046402. doi: 10.1136/bmjopen-2020-046402. BMJ Open. 2021. PMID: 34244264 Free PMC article.
Cited by
-
The Effect of Immunonutrition on Veterans Undergoing Major Surgery for Gastrointestinal Cancer.Fed Pract. 2018 May;35(Suppl 4):S49-S56. Fed Pract. 2018. PMID: 30766401 Free PMC article.
-
Health economic analyses in medical nutrition: a systematic literature review.Clinicoecon Outcomes Res. 2014 Mar 10;6:109-24. doi: 10.2147/CEOR.S53601. eCollection 2014. Clinicoecon Outcomes Res. 2014. PMID: 24648747 Free PMC article.
-
Value of nutrition support therapy in patients with gastrointestinal malignancies: a narrative review and health economic analysis of impact on clinical outcomes in the United States.J Gastrointest Oncol. 2021 Apr;12(2):864-873. doi: 10.21037/jgo-20-326. J Gastrointest Oncol. 2021. PMID: 34012673 Free PMC article. Review.
-
Early enteral nutrition in critical illness: a full economic analysis using US costs.Clinicoecon Outcomes Res. 2013 Aug 23;5:429-36. doi: 10.2147/CEOR.S50722. eCollection 2013. Clinicoecon Outcomes Res. 2013. PMID: 24003308 Free PMC article.
-
Healthcare Resource Utilization and Cost Comparisons of High-Protein Enteral Nutrition Formulas Used in Critically Ill Patients.J Health Econ Outcomes Res. 2022 Jul 1;9(2):1-10. doi: 10.36469/001c.36287. eCollection 2022. J Health Econ Outcomes Res. 2022. PMID: 35854856 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical